A successful 2007 paves the way for future of Nycomed
- Details
- Category: Nycomed
In 2007 Nycomed increased adjusted EBITDA by 31.0% compared to last year to a total of € 1,222.2 million. The strong performance was accompanied in the fourth quarter by major advancements in the US out-licensing efforts that materialised in early 2008. The full year results benefited from increased sales, especially from high-margin products as well as a significant reduction in costs.
Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
- Details
- Category: Amgen
Amgen Inc. (NASDAQ:AMGN) announced the U.S. Food and Drug Administration (FDA) has approved updated safety information, including an updated boxed warning in the labeling information for the class of drugs known as erythropoiesis-stimulating agents (ESAs), including Aranesp(R) (darbepoetin alfa) and EPOGEN(R) (Epoetin alfa).
Pfizer Wins Challenge to Two Main U.S. Patents for Celebrex
- Details
- Category: Pfizer
Pfizer Inc announced today that the Court of Appeals for the Federal Circuit has upheld the two main U.S. patents covering Celebrex, the company's selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA.
DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly
- Details
- Category: Daiichi Sankyo
The Japanese pharmaceutical company DAIICHI SANKYO Group has purchased the European rights to the osteoporosis medication EVISTA® from the U.S. Company Eli Lilly and Company. In the process, the company is planning to gain additional sales volume of approximately €80 million.
Genzyme Launches Renvela® in the U.S. for Dialysis Patients
- Details
- Category: Genzyme
Genzyme Corp. (Nasdaq: GENZ) announced the U.S. launch of the phosphate binder Renvela® (sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to secure additional approvals for the product. Genzyme has submitted a marketing authorization application to the European Medicines Agency seeking approval of Renvela for the control of serum phosphorus in chronic kidney disease patients regardless of whether they are on dialysis.
Pfizer Presents New Opportunities for Global Growth
- Details
- Category: Pfizer
Pfizer Inc. reviewed strategies to accelerate and refocus Pfizer's pipeline and capture new opportunities for global growth at a meeting for investment analysts. "We have made real changes in how we operate our business â in our structure, culture and leadership â so that we have a much stronger foundation in place for pursuing the many opportunities before us," said Chairman and CEO Jeff Kindler.
FDA grants Priority Review For Promacta/Revolade (Eltrombopag)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline announced that the United States Food and Drug Administration (FDA) has granted Priority Review for Promacta®/Revolade® (eltrombopag) for the short-term treatment of patients with chronic idiopathic thrombocytopenic purpura (ITP).
More Pharma News ...
- Court decides against Bayer's Yasmin® patent
- Pfizer to Acquire Serenex to Extend Oncology Pipeline
- Update on GSK's malaria treatments: Dacart and Lapdap
- Johnson & Johnson Diabetes Institute To Provide Education, Training to Health Professionals
- Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
- The Bayer Group once again considerably improved its sales and earnings in 2007
- Celebrity Chef Offers Recipes and Shortcuts in the Kitchen to People with Rheumatoid Arthritis